GHR and Mental deterioration: Because cognitive symptoms are less affected by dopaminergic medication than motor symptoms, and because decline in cognition is variable but clinically important in PD [30], we investigated whether baseline levels of BSP, OMD, ACY1, or GHR predicted subsequent rates of cognitive decline.